Fluticasone Furoate
Vanflyta (quizartinib) is a targeted oral medication classified as a FLT3 inhibitor, designed specifically for adults with FLT3-ITD positive acute myeloid leukemia (AML). This drug is used primarily in patients whose cancer has returned (relapsed) or did not respond to initial treatment (refractory). By blocking the FLT3 receptor, Vanflyta helps slow the growth and spread of leukemia cells.
Vanflyta is a FLT3 inhibitor used to treat adults with FLT3-ITD positive acute myeloid leukemia that has relapsed or is refractory to initial therapy.
Key facts at a glance
- RxNorm
- 2643055
- Generic
- Vanflyta
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Vanflyta is indicated for the treatment of adult patients with relapsed or refractory FLT3-ITD positive acute myeloid leukemia (AML). It is specifically effective for cancers driven by the FLT3-ITD mutation, which is found in a subset of AML patients.
Vanflyta works as a selective small-molecule inhibitor of the FLT3 receptor tyrosine kinase. By blocking FLT3 signaling, it inhibits the proliferation and survival of leukemia cells that depend on this pathway for growth. This targeted approach helps reduce cancer cells in the bone marrow and blood.
Vanflyta is taken orally once daily, with or without food. Common side effects may include nausea, fatigue, and changes in blood cell counts. The medication requires regular monitoring of blood counts and heart rhythm (QT interval) due to potential cardiac effects. Patients should be monitored for signs of infection, as the drug can lower white blood cell counts. Vanflyta may interact with other medications, so all current drugs should be discussed with a healthcare provider before starting treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy